Biogened (WAR:BGD) Accounts Payable: zł15.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:BGD Biogened SA WAR:BGD
73 GF Score
Price zł20.00
GF Value zł24.13
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Biogened Accounts Payable?

Biogened WAR:BGD +4.71% 73 Accounts Payable is zł15.0 Mil as of Mar. 2026. GuruFocus rates WAR:BGD with a GF Score™ of 73/100 and a GF Value™ of zł24.13 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Biogened's Accounts Payable for the quarter that ended in Mar. 2026 was zł15.0 Mil.

Biogened's quarterly Accounts Payable increased from Sep. 2025 (zł11.4 Mil) to Dec. 2025 (zł13.5 Mil) and increased from Dec. 2025 (zł13.5 Mil) to Mar. 2026 (zł15.0 Mil).

Biogened's annual Accounts Payable declined from Dec. 2023 (zł15.2 Mil) to Dec. 2024 (zł14.7 Mil) and declined from Dec. 2024 (zł14.7 Mil) to Dec. 2025 (zł13.5 Mil).

Biogened Accounts Payable Historical Data

* Premium members only.

The historical data trend for Biogened's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogened Accounts Payable Chart

Biogened Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.89 10.17 15.17 14.71 13.54

Biogened Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.68 12.87 11.41 13.54 15.04
WAR:BGD
73GF Score
Biogened SA WAR:BGD
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogened Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of zł15.0 Mil mean?
Biogened (WAR:BGD) has a Accounts Payable of zł15.0 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Biogened and its competitors.
Is Biogened's Accounts Payable too high?
Biogened's current Accounts Payable is zł15.0 Mil. Overall, Biogened has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biogened's Accounts Payable compare to ZTS and UTHR?
Biogened's Accounts Payable of zł15.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Biogened and its competitors. Biogened's current Accounts Payable is zł15.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogened stock overvalued right now?
Based on GuruFocus' analysis, Biogened (WAR:BGD) is currently considered Modestly Undervalued. The stock's GF Value™ is zł24.13, compared to a current price of zł20.00 — trading 17.1% below its estimated fair value. The current Accounts Payable is zł15.0 Mil. Biogened's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Biogened (WAR:BGD), the current Accounts Payable is zł15.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogened (WAR:BGD) Overvalued in 2026?

Based on GuruFocus' analysis, Biogened stock appears to be undervalued. The current stock price of zł20.00 is trading 17.1% below its estimated GF Value™ of zł24.13. GuruFocus considers Biogened to be Modestly Undervalued.

Key valuation signals for WAR:BGD:

  • Accounts Payable: zł15.0 Mil
  • GF Value™: zł24.13 vs. price of zł20.00 (17.1% below fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the WAR:BGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogened Business Description

Address Ulica Pojezierska 99, Lodz, POL, 91-342
Biogened SA is involved in manufacturing cosmetic and hygiene products. It also designs, produces, and markets safe, effective dermo-cosmetics under the Dermedic brand. The company's products include Dermocosmetics, Thermal water, and Pharmaceutical manufacturing conditions.
73GF Score

Get the complete analysis for WAR:BGD

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł20.00
Price
zł24.13
GF Value